Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report.

Tan-Kam T, Suthisisang C, Pavasuthipaisit C, Limsila P, Puangpetch A, Sukasem C.

Pharmgenomics Pers Med. 2013;6:3-7. doi: 10.2147/PGPM.S36782. Epub 2013 Jan 11.

2.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
3.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
4.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
5.

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

de Leon J, Susce MT, Murray-Carmichael E.

Mol Diagn Ther. 2006;10(3):135-51. Review.

PMID:
16771600
7.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303
8.

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.

de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ.

J Clin Psychiatry. 2005 Jan;66(1):15-27.

PMID:
15669884
9.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
11.

A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.

Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL.

Pediatrics. 1999 Dec;104(6):1300-11.

PMID:
10585981
12.

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.

Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S.

Clin Chem. 2005 Feb;51(2):376-85. Epub 2004 Dec 8.

13.

A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.

Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R.

CNS Drugs. 2008;22(8):693-704.

PMID:
18601306
14.

Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication.

Pułczyńska A, Łukaszkiewicz J, Wojnar M, Tomaszewski P, Kubiak-Tomaszewska G, Pachecka J.

Acta Pol Pharm. 2011 Jan-Feb;68(1):9-13.

15.

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.

Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.

J Clin Psychiatry. 2008 Dec;69(12):1938-47. Epub 2008 Dec 2.

PMID:
19192455
16.

Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.

ter Laak MA, Temmink AH, Koeken A, van 't Veer NE, van Hattum PR, Cobbaert CM.

Pediatr Neurol. 2010 Sep;43(3):159-62. doi: 10.1016/j.pediatrneurol.2010.04.004.

PMID:
20691935
17.

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.

Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.

Pediatrics. 2003 Nov;112(5):e404.

PMID:
14595084
18.

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

May DE, Kratochvil CJ.

Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.

PMID:
20030423
19.

Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.

Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J, Sasvari-Szekely M, Nemoda Z.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1431-5. doi: 10.1002/ajmg.b.30704.

PMID:
18214865
20.

A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, Onyango AN, Forehand G, Nguyen A, Waxmonsky J.

Pediatrics. 1999 Apr;103(4):e43.

PMID:
10103335
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk